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0.001]. Moreover, respondents from urban areas were found to have better knowledge 
(12.06 ± 3.82) than rural residents (8.38 ± 4.92, t = 20.0), (P = < 0.001). While, in term 
of level of income those with high income (12.37 ± 3.79) have signiﬁ cantly better 
knowledge than low income (8.00 ± 4.85), [F = 5.5, P < 0.001]. CONCLUSIONS: The 
level of knowledge about TB among TB patients was a low, Therefore, there is a need 
for massive health education campaign to be undertaken by policymakers in order to 
improve TB patients’ knowledge toward TB. 
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OBJECTIVES: The use of long-acting beta agonists (LABAs) has raised safety concerns, 
especially the potential for severe asthma exacerbations (SAEs). The purpose of this 
review was to review the published safety outcomes researches about LABA therapy and 
compare disease epidemiologic trends. METHODS: A systematic literature review was 
conducted with the speciﬁ c focus on safety outcomes research from clinical trials, meta-
analyses, and post-marketing studies. Patients with asthma were reviewed and compared 
between races, and between age groups. SAEs were deﬁ ned as either asthma-related 
death, hospitalization or emergency room visits. Seven major studies were identiﬁ ed and 
reviewed. Annual mortality rate and SAE trends for asthmatic patients and subgroup 
of African American patients were compared. RESULTS: The prevalence of asthma 
increased from 5% in 1992 to 7.8% in 2006, while mortality rate decreased from 1.7 
per 100,000 in 1999 to 1.2 per 100,000 in 2006. Multiple clinical trial data showed 
that LABA monotherapy may be associated with increased risk of asthma exacerbation 
or asthma related death. On the other hand, meta-analyses showed that the use of LABA 
with ICS may be associated with positive outcomes including symptoms reduction, 
quality of life improvement, reduced rate of exacerbations and severe exacerbation. Due 
to the limited data, the relationship between LABAs and an increased risk of severe 
asthma exacerbation is unclear, especially in pediatric and African American patients. 
Due to safety concerns, the US FDA made several label changes to warn the public about 
LABA therapy and has requested more assessments of LABA use in asthma patients. 
CONCLUSIONS: The safety outcomes of the use of LABAs for the asthma treatment 
remain controversial. More well-design research is required to assess the risk of SAEs 
related to LABA therapy in different populations. 
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OBJECTIVES: To estimate the direct out-of-pocket medical costs of treating major 
diseases attributable to smoking in India. METHODS: Indian data on burden of 
smoking related illnesses was compiled on lines of the BENESCO (Beneﬁ ts of smoking 
cessation on outcomes) model by secondary analysis of existing datasets from census 
and National Sample Survey (NSS), 2004. The prevalence of smoking(cigarettes and 
bidis) was estimated by adjusting census projected population data with smoking rate 
found in the National Family & Health Survey–3 (NFHS-3), 2005–2006. Data on age 
and gender-wise disease prevalence and unit cost of treatment of diseases was obtained 
from NSS. A prevalence-based, disease-speciﬁ c approach was used to estimate the 
direct medical costs of treating cancer and other tumors, bronchial asthma, tubercu-
losis, respiratory diseases, hypertension and coronary heart disease attributable to 
smoking. RESULTS: Analysis of data from NFHS–3 estimated that there were 98.2 
million male and 4 million female smokers in India between 15 to 49 years of age. A 
total of 1.1 million hospitalizations and 90.5 million outpatient visits for 6 major 
diseases among adults were attributed to smoking annually. The total annual direct 
out-of-pocket medical cost for treating 6 major diseases was found to be Indian 
National Rupees 198 billion (US$ 4.4b). The total cost attributable to smoking was 
estimated to be INR 46 billion (US$ 1b) (i.e., 23% of the total); INR 33.8 billion 
(US$ 761m) for outpatient care and INR 12.3 billion (US$ 276m) for inpatient care. 
The total annual smoking attributable cost of treatment was highest for heart disease 
at INR 14.5 billion (US$ 327m) followed by bronchial asthma INR 8.8 billion (US$ 
199m) and hypertension INR 8.6 billion (US$ 195m). CONCLUSIONS: The smoking 
epidemic in India is a major preventable public health problem. The direct out-of-
pocket medical costs of treating major diseases attributable to smoking are high. 
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OBJECTIVES: The aim of the current study was to determine the burden of illness 
associated with uncontrolled asthma in both the United States and Japan. METHODS: 
Data were obtained from the 2009 US and 2008 Japan National Health and Wellness 
Surveys (NHWS), cross-sectional Internet-based surveys of adults. Only patients who 
were diagnosed with asthma were included in the analyses. Using the Asthma Control 
Test (ACT), each asthma patient was categorized as having controlled or uncontrolled 
asthma and these groups were compared on health-related quality of life (mental 
component summary (MCS) and physical component summary (PCS) scores of the 
SF-12v2), the number of emergency room (ER) visits, and the number of hospitaliza-
tions controlling for demographics (country, age, gender, ethnicity, income, education) 
and patient characteristics (BMI and Charlson comorbidity index) in multiple regres-
sion and generalized linear models. RESULTS: In Japan, 648 patients (3.2%) were 
diagnosed with asthma while 6481 patients (8.5%) were diagnosed with asthma in 
the United States. Even after adjusting for demographics and patient characteristics, 
those with uncontrolled asthma reported signiﬁ cantly lower levels of MCS scores (M-adj 
= 42.5 vs. 45.9, P < 0.0001). However, not only were PCS scores signiﬁ cantly lower 
among uncontrolled asthma patients (M-adj = 41.7 vs. 47.4, P < 0.0001), but the dif-
ferences between controlled and uncontrolled patients was signiﬁ cantly greater in the 
United States (b = 4.4, P < 0.0001). The number of hospitalizations (M-adj = 0.61 vs. 
0.23, P < 0.0001) and ER visits (M-adj = 0.51 vs. 0.24, P < 0.0001) were both signiﬁ -
cantly higher for those with uncontrolled asthma. The effect on ER visits was signiﬁ -
cantly stronger in the United States than in Japan (b = 8.2, P < 0.01). CONCLUSIONS: 
Although the prevalence of asthma in the United States and uncontrolled asthma was 
greater than that of Japan, uncontrolled asthma patients in both countries exhibited 
a signiﬁ cantly worse health outcome proﬁ le. 
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OBJECTIVES: Appropriate use of combined inhalation therapies for airway disease 
patients is likely to reduce the undesirable health utilization, improve patients’ health-
related quality of life, smooth the decline of pulmonary function and prevent the 
mortality. A secondary data analysis was performed to describe the utilization of two 
types of combined inhaler therapies among the patients diagnosed with airway diseases 
for quality improvement of medical care. METHODS: The claimed administration 
data with visits using two types of combined inhalers (four various dosages and dosage 
forms of Seretide and one Symbicort turbulaler) and the corresponding visits’ diseases 
and demographic information from the 2000-bed medical center afﬁ liated to a medical 
university in Taiwan were retrieved and analyzed. There were up to ﬁ ve diagnoses 
listed in the data set. The descriptive analysis was performed to examine the trends 
of different types of combined inhalers being prescribed for patients diagnosed with 
corresponding airway diseases (i.e., ICD9: 491, 492,493,494,496, 518) in the year of 
2009. RESULTS: Of 2495 patients being prescribed with the combined inhaler thera-
pies (accounted for 9273 total visits), male was dominated (57.7% vs. 42.3%), average 
age was 56.7 ( ± 22.1) year-old and more than 80% were prescribed by the pulmonary 
physicians. Less than 2% had experience of switching inhalers within 1 year. Only 
55.4% were prescribed with coded airway diseases (asthma and COPD accounted for 
25.2% and 21.96%, respectively). Further, 50.6% of them were prescribed with 
inhalers once or twice within 1 year. These prescribing patterns might encounter the 
“drug choice problems.” CONCLUSIONS: The prescribing patters of combined 
inhaler therapies seem problematic in this health setting and need to be examined 
persistently and periodically. To ensure appropriate usages of these inhalers, it is neces-
sary to further study the contributing factors and to investigate the possible resolutions 
to improve the quality of medical care. 
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OBJECTIVES: To identify differences in health-care utilization by race and Latino 
ethnicity among children with asthma and determine the relative contribution of 
predisposing, enabling, and unobserved factors in explaining these differences. 
METHODS: The California Health Interview Survey (CHIS) is a non-institutionalized 
household survey of California residents conducted bi-annually since 2001. Cross-
sectional survey data were a0nalyzed to identify differences by race and Latino ethnicity 
among children with asthma. After adjustment for sample weights and design effects, 
over 400,000 samples in the 2007 CHIS were calculated for children with asthma. 
Disparities in health-care utilization across all race/ethnicity categories were analyzed 
using multivariate logistic regression and negative binomial regression analysis. 
RESULTS: Mexican children with asthma are over 100% more likely to have an 
emergency room (ER) visit in the previous year (P < 0.04) and 58% less likely to have 
a doctor visit (P < 0.049) compared to White children with asthma after controlling 
for confounding variables. Among ethnicity groups, Latino ethnicity is 72% more 
likely to have an ER visit in the previous year and 38% less likely to have a doctor 
visit compared to non-Latino ethnicity. Negative binomial regression results show that 
